Theratechnologies Inc T.TH

You did it again Th... total destruction

[Biobob]

I think it's possible th stock will be between 1.50$ and 2.00$ come winter if nothing good happens with Cancer.  Until then we are on the way.  You see dear Th management, that's what you get when you do stubornly do things your way.  Another near death experience.

[SPCEO1]

I think it is possible that TH could sell between $10 and $15 come Christmas since something very good in cancer seems highly likely to happen between now and then. This could be a third time the stock has a huge move like that, first with Egrifta's early favorable test results, second with Trogarzo and now with TH-1902. If the results are good, even management will not be able to keep the

[Bucknelly21]

I just dont know, i think management does everything opposite the side of what's best... stubborn? Stupidity? Idk but my faith is completely gone in this team beside christian 

[ANALIAS00]

"... Even management will not be able to keep the stock down." ... You want to bet ? LOL

[realitycheck4u]

This post has been removed in accordance with Community Policy

[SPCEO1]

I do think they actually care about it but I agree with the rest of what you said. To not be able to spin a positive story the market would eagerly embrace in the middle of perhaps the biggest bull market of all time and instead to fail at that even when blatantly criminal enterprises are succeeding at it leading to a horrendous offering while everyone else is selling stock at exorbitant prices

[Biobob]

If you voted for them you must accept the result.  If you vote for them again you are endorsing it once again.

[palinc2000]

I think the problem is the lack of confidence in the science...I dont know of any  external oncology expert nor any KOL s who have  made any  positive comments on this PDC...Usually the  anticipation  ball starts rolling at the beginning of a clinical trial and picks up speed along the way and culminates or dissipates upon release of results....Soleus are investors not

[SPCEO1]

I think it might be better stated that there is a lack of knowledge of the science. And there cannot be much knowledge yet because TH has not yet completed phase 1a. But that will be completed soon and, the three posters at the AACR conference starting today may get some attention started and I suspect the cancer conference at the end of June will be very helpful as well.   Savvy

[palinc2000]

I dont think its lack of knowledge.... The SP does not need only institutional investors to rise.There are other Soleus in the universe .Moreover you can be sure that THTX has tried to get coverage by reputable brokers who have got their oncology experts involved and yet not a Single one has opted to initiate coverage even with a highly speculative rating....I have rarely seen such nonchalence

[qwerty22]

I think the clinicians involved in the trial will talk about their patients experiences if they have them and only after the company has gone public. I don't expect a wider response from other KOLs. Sortilin being an unknown target does not lend itself to that as well. It's going to be a slow burn when it comes to getting wider KOL appreciation I think. Clear, strong, unequivocal efficacy

[palinc2000]

Of course clear strong efficacy will/would mountains.....My point is that human nature especially human nature in the investment community makes for very fertile grounds when the risk rewards are as great as in a novel approach in cancer..... Apart from existing shareholders the greed in human nature is absent in our case    

[palinc2000]

Move mountains.... [ quote=palinc2000] Of course clear strong efficacy will/would mountains.....My point is that human nature especially human nature in the investment community makes for very fertile grounds when the risk rewards are as great as in a novel approach in cancer..... Apart from existing shareholders the greed in human nature is absent in our case      

[Wino115]

I think there's some validity to your observation. Both PDCs and sort1 as a target are novel. In the case of sort1, it's unknown outside of a dozen or so medical research institutions.  Which is why if I were running IR for THTX, I would have an entire section in oncology with all the relevant articles summarized (there's a few on TNBC, one on pancreatic tumors, one ovarian, etc..